
    
      This study consists of two phases. The objectives of Phase 1 and Phase 2 are:

      Phase 1: To determine the maximum tolerated dose of lentivirally-transduced CD33-redirected
      CAR-T cells (CD33CART) in children and young adults with relapsed/refractory AML

      Phase 2: To determine the percentage of subjects treated with CD33CART who achieve
      morphologic remission (<5% blasts in marrow) at Day 28 post-CD33CART cell infusion
    
  